

Female (n=4692)




Male (n=5974)




Propensity score matching + adjust

Female (n=4692)




Male (n=5974)





Adjust

Female (n=11356)




Male (n=17329)








Predicted weight change (kg)


Predicted weight change (kg)











Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 11)
3–5 mmol/mol (n=491, event = 6)
0–3 mmol/mol (n=1975, event = 34)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2570, event = 57)
3–5 mmol/mol (n=1749, event = 42)
>5 mmol/mol (n=806, event = 31)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 27)
3–5 mmol/mol (n=1578, event = 31)
0–3 mmol/mol (n=3445, event = 113)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 82)
3–5 mmol/mol (n=330, event = 16)
>5 mmol/mol (n=170, event = 16)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Hazards ratio

Propensity score matching + adjusted

Hazards ratio

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 11)
3-5 mmol/mol (n=491, event = 6)
0-3 mmol/mol (n=1975, event = 34)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2570, event = 57)
3-5 mmol/mol (n=1749, event = 42)
>5 mmol/mol (n=806, event = 31)

Average treatment effect

0.25 0.50 1.0 2.0 4.0

Hazards ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 27)
3–5 mmol/mol (n=1578, event = 31)
0–3 mmol/mol (n=3445, event = 113)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 82)
3–5 mmol/mol (n=330, event = 16)
>5 mmol/mol (n=170, event = 16)
Average treatment effect

0.25 0.50 1.0 2.0 4.0
Hazards ratio

Adjusted

Female (n=22122)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1308, event = 22)
3–5 mmol/mol (n=1104, event = 9)
0–3 mmol/mol (n=4586, event = 64)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=7308, event = 148)
3–5 mmol/mol (n=5438, event = 105)
>5 mmol/mol (n=2378, event = 84)

Average treatment effect

0.50

1.0

2.0

Hazards ratio

Male (n=29930)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=2928, event = 58) 3-5 mmol/mol (n=4223, event = 88)0-3 mmol/mol (n=11693, event = 318)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=9111, event = 264)3-5 mmol/mol (n=1325, event = 55)>5 mmol/mol (n=650, event = 45) Average treatment effect 0.35 0.50 0.71 1.0 1.41 2.0 Hazards ratio

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 7)
3–5 mmol/mol (n=491, event = 3)
0–3 mmol/mol (n=1975, event = 11)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2570, event = 37)
3–5 mmol/mol (n=1749, event = 24)
>5 mmol/mol (n=806, event = 21)
Average treatment effect

0.088 0.125 0.177 0.250 0.354 0.500 0.707 1.00 1.410 2.00
Hazards ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 12)
3–5 mmol/mol (n=1578, event = 17)
0–3 mmol/mol (n=3445, event = 68)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 44)
3–5 mmol/mol (n=330, event = 9)
>5 mmol/mol (n=170, event = 9)

Average treatment effect

0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0

Hazards ratio

Hazards ratio

Propensity score matching + adjusted

Female (n=8235)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=644, event = 7)
3-5 mmol/mol (n=491, event = 3)
0-3 mmol/mol (n=1975, event = 11)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2570, event = 37)
3-5 mmol/mol (n=1749, event = 24)
>5 mmol/mol (n=806, event = 21)

Average treatment effect

0.12 0.25 0.50 1.0 2.0

Hazards ratio

Male (n=8859)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1177, event = 12)
3–5 mmol/mol (n=1578, event = 17)
0–3 mmol/mol (n=3445, event = 68)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2159, event = 44)
3–5 mmol/mol (n=330, event = 9)
>5 mmol/mol (n=170, event = 9)

Average treatment effect

0.062 0.125 0.250 0.500 1.001.410 2.00

Adjusted

Female (n=22122)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1308, event = 12)
3-5 mmol/mol (n=1104, event = 7)
0-3 mmol/mol (n=4586, event = 28)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=7308, event = 86)
3-5 mmol/mol (n=5438, event = 63)
>5 mmol/mol (n=2378, event = 59)

Average treatment effect

0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83
Hazards ratio

Male (n=29930)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2928, event = 30)
3-5 mmol/mol (n=4223, event = 36)
0-3 mmol/mol (n=11693, event = 157)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=9111, event = 122)
3-5 mmol/mol (n=1325, event = 31)
>5 mmol/mol (n=650, event = 24)

Average treatment effect


0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 Hazards ratio

Female (n=8235) Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=644, event = 5) 3-5 mmol/mol (n=491, event = 3) 0-3 mmol/mol (n=1975, event = 13) Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=2570, event = 43) 3-5 mmol/mol (n=1749, event = 36)

>5 mmol/mol (n=806, event = 47)

Average treatment effect

Male (n=8859)




Hazards ratio


Propensity score matching + adjusted

0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83


Hazards ratio




Male (n=8859)



Adjusted




Male (n=29930)



Female (n=8235) Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=644, event = 4) 3–5 mmol/mol (n=491, event = 1) 0–3 mmol/mol (n=1975, event = 7) Predicted HbA1c benefit on GLP1–RA 0–3 mmol/mol (n=2570, event = 15) 3–5 mmol/mol (n=1749, event = 11) >5 mmol/mol (n=806, event = 9)

Male (n=8859)



Hazards ratio

Propensity score matching + adjusted


0.031 0.062 0.125 0.250 0.500

1.00


Hazards ratio

2.00


Average treatment effect




Male (n=8859)



Adjusted



Male (n=29930)




Female (n=9095)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3–5 mmol/mol (n=522, event = 1)
0–3 mmol/mol (n=1982, event = 13)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2786, event = 24)
3–5 mmol/mol (n=1922, event = 16)
>5 mmol/mol (n=1225, event = 25)

Male (n=9459)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)



Propensity score matching + adjusted

0.25

0.50

1.0

Hazards ratio

2.0

4.0

Female (n=9095)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=658, event = 5)
3–5 mmol/mol (n=522, event = 1)
0–3 mmol/mol (n=1982, event = 13)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2786, event = 24)
3–5 mmol/mol (n=1922, event = 16)
>5 mmol/mol (n=1225, event = 25)

Average treatment effect


0.062 0.125 0.250 0.500 1.00 2.00 4.00

Hazards ratio

Male (n=9459)

Average treatment effect

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1216, event = 16)
3-5 mmol/mol (n=1580, event = 12)
0-3 mmol/mol (n=3582, event = 48)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2368, event = 44)
3-5 mmol/mol (n=425, event = 8)
>5 mmol/mol (n=288, event = 7)
Average treatment effect



Adjusted

Female (n=23621)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1329, event = 11)
3-5 mmol/mol (n=1129, event = 2)
0-3 mmol/mol (n=4651, event = 27)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=7622, event = 71)
3-5 mmol/mol (n=5715, event = 46)
>5 mmol/mol (n=3175, event = 51)

Average treatment effect

0.50

1.0

2.0


4.0

8.0

Hazards ratio

Male (n=31231)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2991, event = 32)
3-5 mmol/mol (n=4277, event = 39)
0-3 mmol/mol (n=11983, event = 146)
Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=9520, event = 127)
3-5 mmol/mol (n=1533, event = 33)
>5 mmol/mol (n=927, event = 20)
Average treatment effect



Female (n=10585)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=715, event = 3) 3-5 mmol/mol (n=578, event = 2)0-3 mmol/mol (n=2265, event = 5)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=3249, event = 17)3-5 mmol/mol (n=2267, event = 12)>5 mmol/mol (n=1511, event = 16) Average treatment effect 0.25 0.12 0.50 1.0 2.0

Male (n=12257)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=1359, event = 4) 3-5 mmol/mol (n=1880, event = 8)0-3 mmol/mol (n=4468, event = 32)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=3275, event = 20)3-5 mmol/mol (n=754, event = 10)>5 mmol/mol (n=521, event = 15) Average treatment effect 0.50 2.0

0.25

1.0

Hazards ratio

Hazards ratio

4.0

Propensity score matching + adjusted

Hazards ratio

Female (n=10585)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=715, event = 3) 3-5 mmol/mol (n=578, event = 2)0-3 mmol/mol (n=2265, event = 5)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=3249, event = 17)3-5 mmol/mol (n=2267, event = 12)>5 mmol/mol (n=1511, event = 16) Average treatment effect 0.25 0.50 1.0 2.0 0.12 4.0 Hazards ratio

Male (n=12257)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=1359, event = 4) 3-5 mmol/mol (n=1880, event = 8)0-3 mmol/mol (n=4468, event = 32)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=3275, event = 20)3-5 mmol/mol (n=754, event = 10)>5 mmol/mol (n=521, event = 15) Average treatment effect 0.12 0.25 0.50 2.0 1.0 4.0

Adjusted

Female (n=27172)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=1427, event = 3) 3-5 mmol/mol (n=1240, event = 2)0-3 mmol/mol (n=5185, event = 9)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=8812, event = 28)3-5 mmol/mol (n=6589, event = 22)>5 mmol/mol (n=3919, event = 37) Average treatment effect 0.12 0.18 0.25 0.35 0.50 0.71 1.0 1.41 2.0 2.83 Hazards ratio

Male (n=39256)

Predicted HbA1c benefit on SGLT2i >5 mmol/mol (n=3338, event = 8) 3-5 mmol/mol (n=4948, event = 15)0-3 mmol/mol (n=14228, event = 53)Predicted HbA1c benefit on GLP1-RA 0-3 mmol/mol (n=12515, event = 53)3-5 mmol/mol (n=2630, event = 23)>5 mmol/mol (n=1597, event = 26) Average treatment effect 0.25 0.50 1.0 2.0 Hazards ratio

Female (n=5735)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=517, event = 88)
3-5 mmol/mol (n=386, event = 74)
0-3 mmol/mol (n=1341, event = 220)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=1787, event = 270)
3-5 mmol/mol (n=1256, event = 176)
>5 mmol/mol (n=448, event = 73)

Average treatment effect

0.50
0.71
1.0
1.41
2.0

Male (n=5899)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=843, event = 161)
3–5 mmol/mol (n=1018, event = 188)
0–3 mmol/mol (n=2196, event = 405)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=1543, event = 260)
3–5 mmol/mol (n=239, event = 44)
>5 mmol/mol (n=60, event = 6)

Average treatment effect

Hazards ratio

Propensity score matching + adjusted

Hazards ratio

Female (n=5735)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=517, event = 88)
3-5 mmol/mol (n=386, event = 74)
0-3 mmol/mol (n=1341, event = 220)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=1787, event = 270)
3-5 mmol/mol (n=1256, event = 176)
>5 mmol/mol (n=448, event = 73)

Average treatment effect

0.50
0.71
1.0
1.41
2.0
Hazards ratio

Male (n=5899)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=843, event = 161)
3–5 mmol/mol (n=1018, event = 188)
0–3 mmol/mol (n=2196, event = 405)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=1543, event = 260)
3–5 mmol/mol (n=239, event = 44)
>5 mmol/mol (n=60, event = 6)
Average treatment effect

0.50
0.71
1.0
1.41
2.0
Hazards ratio

Adjusted

Female (n=14912)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1009, event = 171)
3-5 mmol/mol (n=812, event = 132)
0-3 mmol/mol (n=3125, event = 473)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=4837, event = 659)
3-5 mmol/mol (n=3823, event = 476)
>5 mmol/mol (n=1306, event = 195)

Average treatment effect

0.71

1.0

1.41

Hazards ratio

Male (n=19612)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2089, event = 390)
3–5 mmol/mol (n=2686, event = 466)
0–3 mmol/mol (n=7163, event = 1182)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=6491, event = 908)
3–5 mmol/mol (n=942, event = 144)
>5 mmol/mol (n=241, event = 32)
Average treatment effect

0.71

1.0

1.41
Hazards ratio

2.0

Propensity score matching

Female (n=7385)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=568, event = 90)
3–5 mmol/mol (n=444, event = 62)
0–3 mmol/mol (n=1665, event = 192)
Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2260, event = 220)
3–5 mmol/mol (n=1618, event = 131)
>5 mmol/mol (n=830, event = 94)
Average treatment effect

Male (n=8111)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1120, event = 172)
3–5 mmol/mol (n=1404, event = 188)
0–3 mmol/mol (n=2937, event = 344)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2094, event = 235)
3–5 mmol/mol (n=384, event = 47)
>5 mmol/mol (n=172, event = 13)

Average treatment effect

Hazards ratio

Propensity score matching + adjusted

0.50

0.71

1.0

Hazards ratio

1.41

Female (n=7385)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=568, event = 90)
3-5 mmol/mol (n=444, event = 62)
0-3 mmol/mol (n=1665, event = 192)

Predicted HbA1c benefit on GLP1-RA
0-3 mmol/mol (n=2260, event = 220)
3-5 mmol/mol (n=1618, event = 131)
>5 mmol/mol (n=830, event = 94)

Average treatment effect

0.50

0.71

1.0

1.41

Hazards ratio

Male (n=8111)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1120, event = 172)
3–5 mmol/mol (n=1404, event = 188)
0–3 mmol/mol (n=2937, event = 344)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=2094, event = 235)
3–5 mmol/mol (n=384, event = 47)
>5 mmol/mol (n=172, event = 13)

Average treatment effect

0.50

0.71

1.0

1.41

2.0

Hazards ratio

Adjusted

Female (n=18537)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=1095, event = 151)
3–5 mmol/mol (n=941, event = 123)
0–3 mmol/mol (n=3752, event = 428)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=5935, event = 580)
3–5 mmol/mol (n=4688, event = 396)
>5 mmol/mol (n=2126, event = 214)

Average treatment effect

0.71

1.0

1.41

Hazards ratio

Male (n=25385)

Predicted HbA1c benefit on SGLT2i
>5 mmol/mol (n=2552, event = 386)
3–5 mmol/mol (n=3601, event = 470)
0–3 mmol/mol (n=9114, event = 1085)

Predicted HbA1c benefit on GLP1–RA
0–3 mmol/mol (n=8166, event = 794)
3–5 mmol/mol (n=1404, event = 132)
>5 mmol/mol (n=548, event = 56)

Average treatment effect

0.71

1.0

1.41

Hazards ratio